Compare AR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AR | BMRN |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | 632 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.4B |
| IPO Year | 2013 | 1999 |
| Metric | AR | BMRN |
|---|---|---|
| Price | $39.02 | $49.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 18 |
| Target Price | $47.13 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 4.2M | 1.7M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 1.72 | 0.54 |
| Revenue | ★ $5,275,823,000.00 | $1,313,646,000.00 |
| Revenue This Year | $29.74 | $15.02 |
| Revenue Next Year | $5.07 | $12.23 |
| P/E Ratio | ★ $22.35 | $91.80 |
| Revenue Growth | ★ 21.97 | 17.62 |
| 52 Week Low | $29.10 | $49.26 |
| 52 Week High | $45.75 | $66.28 |
| Indicator | AR | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 56.24 | 32.95 |
| Support Level | $32.86 | N/A |
| Resistance Level | $40.08 | $56.91 |
| Average True Range (ATR) | 1.08 | 1.82 |
| MACD | 0.20 | -0.33 |
| Stochastic Oscillator | 81.77 | 7.34 |
Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.